Protara Therapeutics (TARA) Depreciation & Amortization (CF) (2013 - 2017)
Protara Therapeutics (TARA) posted quarterly Depreciation & Amortization (CF) of $90000.0 for Q1 2026, up 8.43% year-over-year from $83000.0 in Q1 2025, and down 3.23% quarter-over-quarter from $93000.0 in Q4 2025.
Powered by 
Analysis
Protara Therapeutics (TARA) Depreciation & Amortization (CF) (2013 - 2017) Analysis & Trends
Protara Therapeutics (TARA) has reported Depreciation & Amortization (CF) for 14 consecutive years, with $90000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 8.43% year-over-year to $90000.0; the TTM figure through Mar 2026 stood at $369000.0 (up 11.14% YoY), while the FY2025 annual figure was $362000.0, up 9.04% from the prior year.
- Depreciation & Amortization (CF) slipped to $90000.0 in Q1 2026 per TARA's latest filing, from $93000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $107000.0 in Q4 2023 and bottomed at $53000.0 in Q2 2022.
- Historically, Depreciation & Amortization (CF) has averaged $80764.7 across 5 years, with a median of $83000.0 in 2024.
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) soared 366.67% — and 2024, when it decreased 23.36%.
- Protara Therapeutics' Depreciation & Amortization (CF) stood at $75000.0 in 2022, then soared by 42.67% to $107000.0 in 2023, then fell by 23.36% to $82000.0 in 2024, then climbed by 13.41% to $93000.0 in 2025, then dropped by 3.23% to $90000.0 in 2026.
- Business Quant data shows TARA's Depreciation & Amortization (CF) at $90000.0 in Q1 2026, $93000.0 in Q4 2025, and $88000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Protara Therapeutics | 241.28 Mn | 241.28 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2017 | 38,000.00 |
| Jun 30, 2017 | 37,000.00 |
| Mar 31, 2017 | 40,000.00 |
| Dec 31, 2016 | 36,000.00 |
| Sep 30, 2016 | 35,000.00 |
| Jun 30, 2016 | 28,000.00 |
| Mar 31, 2016 | 24,000.00 |
| Dec 31, 2015 | 24,000.00 |
| Sep 30, 2015 | 16,000.00 |
| Jun 30, 2015 | 9,000.00 |
| Mar 31, 2015 | 8,000.00 |
| Dec 31, 2014 | 9,000.00 |
| Sep 30, 2014 | 8,000.00 |
| Jun 30, 2014 | 6,000.00 |
| Mar 31, 2014 | 7,000.00 |
| Dec 31, 2013 | 6,000.00 |